News About: Pharm. Industry


Eli Lilly and Chugai jointly ventured by 50:50 in Japan.

Eli Lilly and chugai Pharmaceutical announced plans to set up a 50: 50 joint venture in Japan called the Chugai Lilly Clinical Research Company. Based in Tokyo, the JV will manage the development of selected Lilly pro...

KPMA and KPA opposed KRPIA attempt to make juridical body.

The KRPIA, an organization of representatives from the foreign invested pharmaceutical companies in business presence of Korea, tried to make this organization be a legal entity, for which the KPMA and the KPA strongl...

Drug industry opposes conversion of 24.17% margin to hospital compensation.

During the past 5 years the drug industry supplied drugs to hospital with 24.17% margins, which has been widely exercised in the hospital markets but the government regarded it as an unofficial deal. Accordingly, the ...

Drug industry opposes conversion of 24.17% margin to hospital compensation.

During the past 5 years the drug industry supplied drugs to hospital with 24.17% margins, which has been widely exercised in the hospital markets but the government regarded it as an unofficial deal. Accordingly, the ...

Overseas pharmaceutical sales information by nation and therapeutic category.

1. Sales by nation. Nation 98 sales(U$1Bil.) Market share (%) G/R(%) USA 99.5 39.6 +11 Japan 38.8 15.4 -1 German...

Hanil Pharm. Co. faces on critical edge of bankruptcy

The management control of Hanil Pharmaceutical company was transferred to Shin Dong-A group as a subsidiary in the general shareholder's meeting last year, but as of Apr. 2 this year the company was unable to pay the ...

Japanese bsuiness operation in Korean drug industry on ever expanding.

Japanese pharmaceutical corporations have engaged in their partial joint venture or licensing business with local business counterpartners, but from the latter part of 1990s they expanded their business management con...

KRPIA proposed imported drug insurance pricing based on G7 ex-factory prices.

The KRPIA asked to the government for the imported drug pricing to be determined on the basis of ex-factory prices exercised at the G7 advanced countries as scheduled to take effect from July 1, this year. On March...

Overall KFDA reforms including clinical study system planned to complete earlier.

Mr. Choi Soo-young, the director of Drug Safety Bureau of KFDA, addressed a lecture at the 45th anniversary meeting of Yakup Shinmoon foundation under the title of "the pharmaceutical issues and policies in 21st centu...

KPMA opens membership to foreign drug companies.

The KPMA decided in the executive meeting on March 24 that the eligibility for KPMA membership widely opened to the foreign multinational drug companies regardless of the manufacturing facility located in Korea if the...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.